MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences,...
Prometheus Biosciences
MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline
US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results...